Immunodominant

Immunodominant is a drug discovery company specializing in progressing innovative research from academia into commercialized products. Our lead program is focused on the development of orally administered direct-acting antivirals for the treatment and prevention of COVID-19. We are organized as a Delaware corportation that holds the IP covering LACTOVID as well as other different combinations of antihistamines, delivery methods (e.g. nasal), and forms (e.g. powder, capsule). Our founder and CEO David Ostrov, PhD, is an immunologist and structural biologist with decades of experience studying SARS coronaviruses. He is one of 32 international experts that serve on the Global Virus Network COVID-19 Taskforce. Expertise in structure-based drug design enables Immunodominant to utilize structural information to identify compounds capable of modifying biological responses, resulting in IP covering novel therapies for prevention and treatment of autoimmune diseases and cancer. For more information about Immunodominant and our newly released Vitale dietary supplement please visit our company website at www.immunodominant.com.